Ra Pharmaceuticals is preparing to launch a Phase 3 clinical trial to assess the therapeutic potential of zilucoplan for the treatment of patients with generalized myasthenia gravis (gMG). This comes after the company’s completion of End-of-Phase 2 interactions with the FDA
Note: Medical information included on this website comes from sources that are noted along with the information. Citing a source on this website does not imply an endorsement by Myasthenia Gravis Minnesota, Inc. (mgMN). Always consult your physician, pharmacist, nurse or other health care professional for advice and expertise regarding the care that is best for you.